CF PHARMTECH

2652
4.5905.17% ( -0.250 )
Delay Closed: Nov 16, 16:08:11

Overview

CF PHARMTECH (2652)

CF PharmTech, Inc. engages in research and development, production, and sale of respiratory drugs and other related medical products in China. It offers Shufeim...

Open
4.840
High
4.840
Low
4.495
Prev. Close
4.840
Volume
1.11M
Turnover
5.10M
Avg Price
4.607
Bid/Ask Ratio
-80.00%
Amplitude
7.13%
52wk High
39.500
Volume Ratio
2.04
Turnover Ratio
0.34%
52wk Low
4.495
HK Mkt Cap
1.48B
Market CapHKD
1.98B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.0181
EPSDynamic
-0.0561
EPSStatic
--
BVPS
3.58
P/B
1.28
HK Shares
321.86M
Dividend YieldTTM
--
DividendTTM
--
Shares
431.61M
Min lot size
100
Currency
HKD

Daily Events

  1. Nov, 16

    Changfeng Pharma opened at HK$4.84 and faded through the session, touching HK$4.50 at 14:44 BJ before closing at HK$4.65, down 3.93% on HK$5.01 million turnover, with the intraday low within 0.1% of the 52-week trough of HK$4.495 set a day earlier. The stock is down 86.31% year to date and 88.23% below its 25 February high of HK$39.50, still under both the MA20 of HK$5.331 and MA60 of HK$8.394. Results are mixed: Q2 2026 revenue of HK$121.4 million rose 58.37% yoy and the net loss narrowed 60.58% to HK$6.07 million, while Q1 revenue fell 18.02% and the loss widened 143.47%. First dosing of inhaled ILD candidate ICF004 in Phase I and a voluntary six-month lock-up extension by core management did not reverse the price weakness; PB is 1.30 and market value HK$2.01 billion. Though Q2 revenue rebounded and the loss narrowed yoy.

  2. Nov, 6

    CF Pharmtech fell 5.75% to HK$5.160 in a spike-and-fade session: it opened at HK$5.470, probed HK$5.155 in the morning, rebounded to HK$5.465 at 13:28 before sliding to the day's low of HK$5.160 at the close on 1.0056 million shares worth HK$5.28 million. The move leaves it just 4.67% above the 52-week low of HK$4.93 set on 3 November, down 84.81% year-to-date and 86.94% below the 25 February peak of HK$39.50, with the price under both MA20 (HK$5.664) and MA60 (HK$9.564). Q2 revenue rose 58.37% year-on-year to HK$121.4 million and the net loss narrowed to HK$6.07 million with per-share loss of HK$0.0148, yet Q1 revenue fell 18.02% with a HK$5.97 million net loss, leaving the P/E negative and P/B at 1.44. Management voluntarily extended its lock-up by six months, the chairman added 19,300 shares near HK$6.92 and buybacks of about HK$499,600 continued, though turnover of only HK$5.28 million suggests thin support.

  3. Nov, 5

    Opening at HK$5.320, which held as the session low, 2652.HK pushed to an 11:34 high of HK$5.505, eased to HK$5.340 in the afternoon and settled at HK$5.475, up 3.60%. The gain extends a roughly 11% rebound from the HK$4.93 record low set on 3 November, supported by core management's voluntary six-month lock-up extension, chairman Liang Wenqing's purchase of 19,300 shares at about HK$6.92, and buybacks of about HK$499,600 on each of 6-8 October. Fundamentals stay mixed: Q2 revenue rose 58.37% year on year to HK$121.4 million with the net loss narrowing to HK$6.07 million, while Q1 revenue fell 18.02% and its HK$5.97 million net loss widened 143.47%; the trailing PE is negative at -302.23 against PB of 1.53. The stock remains below its MA20 of HK$5.693 and MA60 of HK$9.747, down 83.88% year to date from HK$33.96 and 86.14% below the 25 February high of HK$39.50. Though profitability has yet to turn positive and the moving averages keep sloping down.

  4. Nov, 3

    CF Pharmtech fell about 4.3% to HK$5.055 from the prior close of HK$5.285 after a spike-and-fade session: it opened at HK$5.08, touched HK$5.28 in the morning, then slid to HK$4.955 at 14:30 BJ, close to the 52-week low of HK$4.935 set the previous day. Support measures have not halted the slide: core management voluntarily extended its lock-up by six months, chairman Liang Wenqing bought 19,300 shares at about HK$6.92, and the company repurchased roughly 72,400 to 89,300 shares a day on October 6-8 for a combined HK$499,600. Fundamentals are mixed: Q2 2026 revenue rose 58.37% year on year to HK$121.4 million and the net loss narrowed to HK$6.07 million, while Q1 revenue fell 18.02%; PE is negative at -279.32 and PB 1.41 on a HK$2.18 billion market cap. The stock is down 85.1% year to date, 87.19% below its February 25 high of HK$39.5, and trades under its MA20 of HK$5.83. Though turnover was only HK$9.6 million at a 0.58% turnover rate, limiting the scale of selling.

  5. Oct, 22

    Fading from the open, CF PharmTech (2652.HK) printed its session high of HK$5.755 at the 09:30 BJ open, slid to HK$5.375 by 11:39 and closed the afternoon at HK$5.430, down 5.65% on 1.075 million shares worth HK$5.89 million with a 0.33% turnover rate, extending October's retreat under small-cap liquidity pressure. The stock sits only 4.93% above its 52-week low of HK$5.175, 86.25% below the HK$39.50 peak of 25 February, down 84.01% year-to-date and well under MA20 of HK$6.817 and MA60 of HK$11.725. That contrasts with Q2 2026 revenue of HK$121.37 million, up 58.37% year on year, a net loss narrowing 60.58% to HK$6.07 million, and price-to-book of 1.52x, against Q1 revenue that fell 18.02% year on year. Though chairman Liang Wenqing added 19,300 shares near HK$6.92 each, management extended its lock-up by six months and repurchases of about HK$499,600 ran daily from 2 to 8 October, the shares still closed lower.

News